Paul_Andrea

Andrea Paul

Paul_Andrea

Andrea Paul

Partner

Boston + 1 617 526 6081

Andrea Paul is an experienced life sciences attorney and former biotech executive who provides strategic counsel on a wide range of corporate matters to clients at WilmerHale.

Andrea’s practice focuses on counseling life sciences clients across a broad range of issues, including securities laws, corporate governance, public offerings and other capital-raising transactions. She also assists clients with matters involving compensation and benefits, collaborations and licensing, and mergers and acquisitions (M&A).

Prior to joining the firm, Andrea served as Chief Legal Officer and Corporate Secretary at Zentalis Pharmaceuticals, where she led the Legal, Corporate Secretary, Quality and IT functions. Prior to Zentalis, Andrea was the General Counsel and Corporate Secretary of LogicBio Therapeutics, Vice President, Legal at Akebia Therapeutics, and Senior Corporate Counsel at Momenta Pharmaceuticals. While in-house, Andrea played key roles in numerous significant transactions, including Akebia’s merger with Keryx Biopharmaceuticals, a variety of equity financings, royalty monetization, debt facilities, licensing/collaboration agreements and supply agreements.

Andrea began her legal career at an AmLaw 50 firm and then an AmLaw 100 firm advising on public company disclosure, corporate governance, M&A, and a wide variety of financings, including initial public offerings, follow-ons, private investment in public equity offerings (PIPEs), at-the-market facilities (ATMs) and cross-border financings.

A graduate of Harvard Law School, Andrea served as Managing Editor of Volume 121 of The Harvard Law Review. She received her BA in Art History from Columbia University (Columbia College).

Andrea is a speaker on public company disclosure, financing and executive compensation as well as internal investigations. She previously co-chaired the Boston Bar Association’s Securities Law Committee and served as President of the Board for Arts for Learning Massachusetts, a nonprofit that empowers youth across the state through the arts.

Experience

  • STRATEGIC ADVISING

    • Trusted strategic advisor to boards and executives on a broad range of issues, including complex disclosure issues, capital raises, M&A, licensing/collaboration transactions, corporate governance, regulatory, alliance, supply chain, investigations and employment/compensation.
    • Led Legal, Corporate Secretary, Quality and IT functions at Zentalis Pharmaceuticals, led Legal and Corporate Secretary functions at LogicBio Therapeutics, and was a key member of the Legal teams at Akebia Therapeutics and Momenta Pharmaceuticals. 
    • Architect of SEC filings and disclosure strategy across multiple companies, including 10-Ks/20-Fs, 10-Qs, proxy statements, S-1s/F-1s, S-3s, S-4s, and 8-Ks.
    • Implemented legal training programs, contracting processes, publication review processes, contract management systems, and artificial intelligence (AI)-based tools.

  • FINANCINGS AND STRATEGIC TRANSACTIONS

    • Zentalis Pharmaceuticals in its asset sale to Immunome
    • Zentalis Pharmaceuticals in its licensing/collaboration with Immunome
    • Zentalis Pharmaceuticals in its $250 million follow-on offering
    • Akebia Therapeutics in its licensing/collaboration with Vifor Pharma Group
    • Akebia Therapeutics in its $60 million royalty monetization with HealthCare Royalty Management
    • Akebia Therapeutics in its $100 million term loans with Pharmakon Advisors
    • Akebia Therapeutics in approximately $210 million of follow-on offerings
    • Akebia Therapeutics in its merger-of-equals with Keryx Biopharmaceuticals
    • G1 Therapeutics in its Series B and Series C financing rounds and its initial public offering
    • The underwriters in the initial public offering of Bavarian Nordic
    • OXiGENE in multiple follow-on offerings and a PIPE
    • NeuroMetrix in its approximately $13.6 million follow-on offering
    • Wellington Management Company in Mozido’s Series B financing round
    • Solectria Renewables in its sale to Yaskawa Electric
    • The underwriters in Stemline Therapeutics’ follow-on offering
    • AFT Pharmaceuticals in its initial public offering on the NZX and the ASX
    • Statoil Fuel & Retail on its approximately $920 million initial public offering on the Oslo Børs
    • Byggmax Group on its approximately $164 million initial public offering on Nasdaq Stockholm
    • Barclays Bank on over $12 billion of notes offerings
    • Statoil on nearly $5 billion of notes offerings
    • BP on over $3 billion of notes offerings
    • European Investment Bank on $3 billion of notes offerings 
    • Advised numerous biotech clients on a wide variety of agreements, including supply, translational and research agreements
    • Advised numerous life sciences clients on ATM facilities

Insights & News

View all of Andrea's insights & news

Credentials

  • Education

    • JD, Harvard Law School, 2008

      Managing Editor, Vol. 121 of The Harvard Law Review

      cum laude

    • BA, Art History, Columbia University, 2003

      summa cum laude

      Phi Beta Kappa 

      Senior Thesis Prize in Art History

  • Admissions

    • Massachusetts

    • New York

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel